136 related articles for article (PubMed ID: 1822966)
1. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate.
de Biasi R; Rocino A; Miraglia E; Mastrullo L; Quirino AA
Blood; 1991 Oct; 78(8):1919-22. PubMed ID: 1822966
[TBL] [Abstract][Full Text] [Related]
2. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N
Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642
[TBL] [Abstract][Full Text] [Related]
3. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
Goldsmith JM; Deutsche J; Tang M; Green D
Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?
Eichinger S; Pabinger I; Kyrle PA; Köller U; Kier P; Schneider B; Lechner K
Haemostasis; 1992; 22(1):25-31. PubMed ID: 1521824
[TBL] [Abstract][Full Text] [Related]
5. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
[TBL] [Abstract][Full Text] [Related]
6. The impact of a very high-purity factor VIII concentrate on the immune system of HIV-infected haemophiliacs: a randomized, two-year comparison with a high-purity concentrate.
de Biasi R; Rocino A; Quirino AA; Miraglia E; Ziello L
Haemophilia; 1996 Apr; 2(2):82-7. PubMed ID: 27214013
[TBL] [Abstract][Full Text] [Related]
7. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
Seremetis SV
Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
[No Abstract] [Full Text] [Related]
8. Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group.
Gjerset GF; Pike MC; Mosley JW; Hassett J; Fletcher MA; Donegan E; Parker JW; Counts RB; Zhou Y; Kasper CK
Blood; 1994 Sep; 84(5):1666-71. PubMed ID: 7915149
[TBL] [Abstract][Full Text] [Related]
9. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D
Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234
[TBL] [Abstract][Full Text] [Related]
10. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
[TBL] [Abstract][Full Text] [Related]
11. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
Molina Alejandro R; Lorenzo Herrero JI; Haya Guaita S; Querol Fuentes F; Aznar Lucea JA
Rev Clin Esp; 1996 Jun; 196(6):365-9. PubMed ID: 8767071
[TBL] [Abstract][Full Text] [Related]
12. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
[TBL] [Abstract][Full Text] [Related]
13. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C
Thromb Haemost; 1994 Aug; 72(2):214-7. PubMed ID: 7831654
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin 2 receptor and soluble CD8 levels in previously treated human immunodeficiency virus-negative hemophiliacs multiply transfused with a monoclonal antibody-purified factor VIII concentrate.
Smid WM; Martens A; van der Meer J; Hegge-Paping CS; Halie MR
Transfusion; 1997 Jan; 37(1):86-9. PubMed ID: 9024495
[TBL] [Abstract][Full Text] [Related]
15. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM
Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077
[TBL] [Abstract][Full Text] [Related]
16. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
Teitel JM; Card R; Strawczynski H
Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to HIV in Israeli hemophiliacs: relationship between serological profile and disease development.
Orgad S; Malone G; Zaizov R; Marinowitz U; McLane MF; Umiel T; Cohen IJ; Vogel R; Cohen-Avishai O; Ramot B
AIDS Res Hum Retroviruses; 1987; 3(3):323-32. PubMed ID: 3124874
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies.
Brettler DB; Forsberg AD; Levine PH; Petillo J; Lamon K; Sullivan JL
Blood; 1989 May; 73(7):1859-63. PubMed ID: 2496775
[TBL] [Abstract][Full Text] [Related]
19. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y).
Evans JA; Pasi KJ; Williams MD; Hill FG
Br J Haematol; 1991 Nov; 79(3):457-61. PubMed ID: 1751373
[TBL] [Abstract][Full Text] [Related]
20. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.
Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA
Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]